ANALYSIS OF FINANCIAL STATEMENTS

SANOFI-AVENTIS PAKISTAN LTD.

SUBMITTED TO:
SIR SHOAIB WASIM

SUBMITTED BY:
ABDUL WAHAB

Dated:
7th January, 2013
 SANOFI-AVENTIS PAKISTAN LTD. 1
ANALYSIS OF FINANCIAL STATEMENTS

TABLE OF CONTENT

1. Introduction to Sanofi International------------------------------------------------------------- 02

2. Introduction to Sanofi International------------------------------------------------------------- 03

3. Corporate History------------------------------------------------------------------------------------- 03

4. Vision ---------------------------------------------------------------------------------------------------- 03

5. Mission -------------------------------------------------------------------------------------------------- 03

6. Key Members ------------------------------------------------------------------------------------------ 04

7. Market Share ------------------------------------------------------------------------------------------ 04

8. Horizontal Analysis -----------------------------------------------------------------------------------05

9. Vertical Analysis---------------------------------------------------------------------------------------06
10. Analysis ------------------------------------------------------------------------------------------------07
11. Company Ratios --------------------------------------------------------------------------------------08
12. Comparison with Industry ------------------------------------------------------------------------09
13. Interpretation ----------------------------------------------- --------------------------------------- 09
14. Graphical Representation -------------------------------------------------------------------------10
15. Criticism ---------------------------------------------------------------------------------------------- 13
16. Recommendations --------------------------------------------------------------------------------- 13
17. Financial Statements ------------------------------------------------------------------------------ 14

 Balance Sheet
 Profit & Loss Account
 Cash Flow Statement
 Statement of Owners’ Equity
 SANOFI-AVENTIS PAKISTAN LTD. 2
ANALYSIS OF FINANCIAL STATEMENTS

INTRODUCTION
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions
focused on patients’ needs. Sanofi has core strengths in healthcare, with 7 growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and
the new Genzyme. Through the acquisition of Genzyme, Sanofi has strongly reinforced its footprint in rare
diseases.
SANOFI PROFILE
 A global healthcare leader
 A diversified offering of medicines, consumer healthcare products, generics and animal health
 A world leader in human vaccines
 A broad and balanced presence on both traditional and emerging markets
 More than 110,000 employees in 100 countries
 2011 net sales: a €33.4 billion, growth of 3.2%

SANOFI’S HISTORY
 Sanofi is the heir to a long history that of the major scientific advances and the reputations of major
industrial laboratories in the development of chemistry, pharmacy and medicine.

In 1718, Laboratories Midy was founded by a family of pharmacists. In 1980, the Clin Midy group
was acquired by Sanofi.
 Laboratories Dausse was founded in 1834 and is Laboratories Robert & Carrière in 1901. They
merged to create Synthélabo in 1970.
 In 1860 the pharmacist Etienne Poulenc created Wittmann et Poulenc Jeune. And in 1910 it was
Rorer’s turn. The two companies eventually merged to form Rhône-Poulenc Rorer in 1990.
 In 1863, a group of chemists, sales people and workers embarked on the manufacture of dyes in a
small factory to the west of the town of Höchst in Germany. This was the origin of the company
Hoechst, which merged with Roussel (founded in 1911) to form Hoechst Marion Roussel.
 In 1887, Marcel Mérieux, a student of Louis Pasteur, founds the Mérieux Biological Institute which,
in 2004 became Sanofi Pasteur, the Sanofi’s vaccine division.
And more recently
 The two young groups Sanofi and Synthélabo merged in May 1999 to create a major new
pharmaceutical player.
 In December 1999, Rhône-Poulenc and Hoechst Marion Roussel formalized their merger with the
creation of the Franco-German group Aventis, one of the world’s largest pharmaceutical companies.
 In August 2004, Sanofi-Synthelabo acquired Aventis. The takeover was finalized on December 31 of
that year, giving birth to sanofi-aventis.
 On May 6, 2011, sanofi-aventis simplified its name to Sanofi.
 SANOFI-AVENTIS PAKISTAN LTD. 3
ANALYSIS OF FINANCIAL STATEMENTS

SANOFI PAKISTAN LTD.

INTRODUCTION
Sanofi-aventis Pakistan limited has a strong presence in Pakistan. With over 1000 employees working every
day with the commitment to improve health and wellness across the country, sanofi-aventis Pakistan
limited ranks amongst the top ten pharmaceutical firms in Pakistan.

Corporate Profile
The company was incorporated on December 8, 1967 as Hoechst Pakistan Limited. Manufacturing of
pharmaceuticals and specialty chemicals started in 1973. In 1977 the company went public and was listed on the
Karachi Stock Exchange. Agrochemical formulation started in 1985.

In 1996, the Agriculture business was spun off into a separate legal entity called AgrEvo Pakistan (Private) Limited,
and the following year, Specialty Chemicals business was sold to Clariant Pakistan Limited. Hoechst Pakistan Limited
changed its name to Hoechst Marion Roussel (Pakistan) Limited in June 1996, and the core business was then
restricted to pharmaceutical activities. In December 1999, Hoechst AG & Rhone Poulenc S.A. globally merged their
life sciences business into a new company known as Aventis S.A. The name of the company in Pakistan was changed
to Aventis Pharma (Pakistan) Limited in November 2000.

In line with the amalgamation globally, Aventis Pharma (Pakistan) Limited was merged locally with Rhone Poulenc
Rorer Pakistan (Private) Limited and the company changed its name to Aventis Limited from April 2003. During 2004
Aventis S.A. was acquired by Sanofi synthelabo to form a company called sanofi-aventis S.A. Consequently in
September 2005 the name of the company was changed to sanofi-aventis Pakistan limited.

VISION
To become a diversified healthcare leader, focused on patients’ needs
Valued by patients & healthcare providers
Sought-after as an employer
Respected by the scientific community & our competitors

MISSION
Our core strategy is to:
Create value by rapidly launching and successfully marketing innovative
pharmaceuticals that satisfy unmet medical needs in large patient
populations.
Focus commercial resources on strategic brands to drive sales growth and
maximize the value of existing and new global brands.
Aggressively recruit and retain top talent, enhancing our capabilities in drug
innovation and commercialization.
 SANOFI-AVENTIS PAKISTAN LTD. 4
ANALYSIS OF FINANCIAL STATEMENTS

KEY MEMBERS
Board of Directors
 Syed Babar Ali -Chairman
 Tariq Wajid- Managing Director
 Arshad Ali Gohar
 Syed Hyder Ali
 Shailesh Ayyangar (Alternate Asim Jamal)
 Francois Jean Louis Briens (Alternate Shakeel Mapara)
 Jean-Marc Georges (Alternate Syed Muhammad Ali Hasani)
 Mohammad Ibadullah
 Amanullah Khan
Company Secretary
Muhammad Irfan
Auditors
Ernst & Young Ford Rhodes Sidat Hyder
Chartered Accountants

MARKET SHARE
Today, Sanofi is the 6th largest pharmaceutical company in Pakistan with a market share and growth rate
of 4.1% and 16% respectively.

(MARKET VOLUME IN 2010)

 SANOFI-AVENTIS PAKISTAN LTD. 5
ANALYSIS OF FINANCIAL STATEMENTS

HORIZONTAL ANALYSIS
 SANOFI-AVENTIS PAKISTAN LTD. 6
ANALYSIS OF FINANCIAL STATEMENTS

VERTICAL ANALYSIS
 SANOFI-AVENTIS PAKISTAN LTD. 7
ANALYSIS OF FINANCIAL STATEMENTS

ANALYSIS

HORIZONTAL
 Cost of Sales is increased by 26.8% which is alarming as it is more than 70% of sales. This change is due
to increased in Raw Material and packaging. Packaging cost increased as company’s Export increased
in 2011 by 113% as compare to 2010 which causes high packaging cost. (NOTE 22, 23.0)
 Distribution, Selling and admin expense increase by 25.2%. This change is due to increase in
distribution and marketing expenses by 35%. As company face decline in sales in 2010 by 9% so they
increased their marketing and distributors (Note:23.1.1)
 Other Operating income is increased by 60.8%. Company received Rs.767,000 interest on term
deposit. Company also received contribution from SANOFI AVENTIS SINGAPORE of amount
Rs.65,670.000 and SANOFI PASTEUR of amount Rs.64,983,000 for support in vaccine and Pharma
trading (Note:25.1)
 Fixed assets are increased by 10.6 %. The change is due to increase in Capital work in progress by
109%. (Note:3.2)
 Other non-Current assets are increased by 20%.As Company’s intangible assets increased by 850%.
Company bought new licenses of Rs.70 million during 2011.(Note:4)
 Long term liabilities decreased by 44%. Company has paid installment of its two year loan from
commercial bank.(Note:16-17)
 Current Liabilities increased by 83.9%. As Trade Creditors liability increased by 71%. (Note:19)
 Cash generation from operations is decreased by 58.9% as company’s credit sales are 47% greater than
2010. Income tax paid is also increased by 130%. (Note:29,30)
 Cash used in investing is increased by 101.4% as Capital Expenditure is increased by 86%.
 Cash used in financing is increased by 200% as company paid long term loan.

VERTICAL

 Cost of sale increased by 1.8% as compare to 2010 (73.3 – 71.5) as raw material cost and packaging
cost increased.
 Fixed assets decreased by 6.7% though fixed assets are greater than 2010’s amount but as compare
to increased in total assets the increased lesser. Mean company is increasing their current assets
there for their current ratio is also improved.
 Company’s current liabilities are increasing while noncurrent liabilities are decreasing means
company is improving their current ratio as well as quick ratio.
 SANOFI-AVENTIS PAKISTAN LTD. 8
ANALYSIS OF FINANCIAL STATEMENTS

Company Ratios
Liquidity Ratios 2011 2010 2009 2008 2007 2006
Current Ratio Times 1.1 1.4 1.0 1 1.3 1.5
Quick Ratio Times 0.5 0.5 0.4 0.3 0.4 0.5
Net Working Capital Rs. 000 313,924 555,195 - 38,124 - 27,776 382,834 413,844
Operating Cycle Days 35 53 46 57 70 86
Current assets / Total assets % 64.2 57.5 59.2 59.3 66.9 63.9
Activity Ratios
Inventory Turnover Times 3.9 3.7 4.4 2.9 2.9 2.6
Average No of Days inventory in stock Days 94 98 83 124 125 137
Accounts Receivable Turnover Times 33.3 24.5 27 30 27.3 33.1
Average Collection Period Days 11 15 14 12 13 11
Creditors Turnover Times 6 6 7.1 4.6 5.3 5.8
Fixed Assets Turnover Times 4.9 4.4 4.8 3.6 4.9 5.4
Operating Fixed Assets Turnover Times 5.9 4.8 8.7 6.7 6 9.7
Total Assets Turnover Times 1.7 1.8 2 1.5 1.6 1.9
Leverage
Debt to Equity Ratio Times 0.8 0.5 1.1 0.8 0.5 0.3
Interest Earned Times 4.7 4.1 2.9 2 2.8 7.4
Fixed Assets to Equity Times 1 1 1.1 1.1 0.7 0.6
Financial Leverage Times 1.9 2.2 2.5 4.5 2.4 1.8
Profitability Ratios
EBITDA* Rs. 000 761,912 703,290 509,164 274,185 273,956 476,428
Net Profit Margin % 3 3.6 2.5 0.9 1.9 5.9
Gross Profit Margin % 26.6 28.5 24.2 24.3 27.8 32.6
Operating Profit Margin % 7 8.6 5.7 3.9 4.6 10.8
Return on Assets % 5.2 6.7 4.9 1.3 3.1 11.4
Return on Equity % 14.3 15.3 12.9 3.4 6.8 20.3
Return on Capital Employed % 18.9 24 14.2 8.4 10.7 28.3
Financial Charges / Net Income % 49.3 58 78.3 227.6 86.3 24.4
Market Value
Market Value Per Share Rs. 145 142 145 211 276 252
Market / Book Ratio Times 0.9 0.9 1.1 1.8 2.4 2.2
Earnings per share (after tax) Rs. 23.8 23.23 17.4 3.97 7.81 23.54
Price Earnings Ratio Times 6.1 6.1 8.4 53.2 35.4 10.7
Dividend per Share Rs. 10 10 7 1.4 4.4 7.1
Dividend Yield % 7 7 4.8 0.7 1.6 2.8
Dividend Cover Times 2.2 2.2 3 2.6 3.7 3.3
Payout Ratio (after tax) % 42 43.1 40.3 35.3 56.4 30.2
Market Capitalization Rs. M 1,398 1,370 1,398 2,035 2,662 2,431
Break-up Value Rs. 166.03 151.52 134 115.77 115.52 115.72
 SANOFI-AVENTIS PAKISTAN LTD. 9
ANALYSIS OF FINANCIAL STATEMENTS

Company Vs Industry

Sanofi Industry
KEY INDICATORS 2011 2010 Change 2011 2010 Change
Current Ratio 1.1 1.4 -21.43% 2.58 2.49 3.62%
Quick Ratio 0.5 0.5 0.00% 0.60 0.61 -1.09%
Inventory Turnover 3.9 3.7 5.41% 3.97 4.16 -4.56%
Account Receivable Turn Over 33.3 24.5 35.92% 17.10 37.9 -54.92%
Total Assets Turnover 1.7 1.8 -5.56% 1.64 1.55 5.79%
Debt to Equity Ratio 0.8 0.5 60.00% 0.43 0.47 -7.86%
COGS as a % of Net Sales 73.4 71.5 2.66% 70.34 73.34 -4.08%
Net Profit Margin 3 3.6 -16.67% 12.80 9.31 37.54%
Return on Assets 5.2 6.7 -22.39% 22.99 16.15 42.38%
Return on Equity 14.3 15.3 -6.54% 33.34 23.70 40.69%
Return on Capital Employed 18.9 24 -21.25% 32.53 22.91 42.03%
Earnings per share (after tax) 23.8 23.2 2.45% 7.44 4.58 62.45%

INTREPITATION

 Current ratio and quick ratio of Sanofi is very low as compare to industry as they have debt ratio
more than that of industry.
 Inventory turnover and account receivable turn over in good as compared to industry as company is
managing its inventory gently and there receivable are recovering more efficiently as compare to
industry.
 Total asset turnover is lesser than industry mean company is not managing their assets effectively.
 Debt to equity ratio of company is greater than industry as company has greater debt than industry.
 ROA, ROE, Net profit margins are very low than industry as company’s profits are low as compare to
industry.
 SANOFI-AVENTIS PAKISTAN LTD. 10
ANALYSIS OF FINANCIAL STATEMENTS

GRAPHICAL REPRESENTATION
ACTIVITY RATIOS & LIQUIDTY RATIOS

Current Ratio Quick Ratio

1.6 0.5
1.4
0.4
1.2
1 0.3
0.8
0.6 0.2
0.4
0.1
0.2
0 0
2011 2010 2009 2008 2007 2006 2011 2010 2009 2008 2007 2006

Inventory Turnover Accounts Receivable

Turnover
5

4 35
30
3 25
20
2
15
1 10
5
0 0
2011 2010 2009 2008 2007 2006 2011 2010 2009 2008 2007 2006

Average Collection Fixed Assets Turnover

Period 6

15 5
4
10 3
2
5
1
0 0
2011 2010 2009 2008 2007 2006 2011 2010 2009 2008 2007 2006
 SANOFI-AVENTIS PAKISTAN LTD. 11
ANALYSIS OF FINANCIAL STATEMENTS

LEVERAGE RATIO

Debt to Equity Ratio Interest Earned

1.2 8
1
6
0.8
0.6 4
0.4
2
0.2
0 0
2011 2010 2009 2008 2007 2006 2011 2010 2009 2008 2007 2006

Fixed Assets to Equity Financial Leverage

1.2 5

1 4
0.8
3
0.6
2
0.4
0.2 1

0 0
2011 2010 2009 2008 2007 2006 2011 2010 2009 2008 2007 2006

PROFITABILITY RATIO

Net Profit Margin Gross Profit Margin

35
6
30
5
25
4
20
3 15
2 10
1 5
0 0
2011 2010 2009 2008 2007 2006 2011 2010 2009 2008 2007 2006
 SANOFI-AVENTIS PAKISTAN LTD. 12
ANALYSIS OF FINANCIAL STATEMENTS

Return on Assets Return on Equity

25
12
10 20
8 15
6
10
4
2 5

0 0
2011 2010 2009 2008 2007 2006 2011 2010 2009 2008 2007 2006

MARKET RATIOS

Earnings per share (after Price Earning Ratio

tax)
60

25 50

20 40

15 30
10 20
5 10
0 0
2011 2010 2009 2008 2007 2006 2011 2010 2009 2008 2007 2006

Payout Ratio (after tax) Dividend Yield

60 8
50
6
40
30 4
20
2
10
0 0
2011 2010 2009 2008 2007 2006 2011 2010 2009 2008 2007 2006
 SANOFI-AVENTIS PAKISTAN LTD. 13
ANALYSIS OF FINANCIAL STATEMENTS

CRITICISM
 Sanofi Aventis has increased sales, profits, and assets. They achieved reduction in long term
liabilities but yet they are far behind then industry. Company has excessive debt as compared to
industry. This factor increases interest expense which causes very low Earning before tax as well as
net income.
FINANCIAL COST ( in Rs. 000 )
2011 2010
SANOFI 113196 130041
INDUSTRY 13537 8857

 Company’s Cost of sales constitutes more than 70% of sales and it is increasing due to increase in
packaging and raw material cost. This is alarming.
 Company has an appeal filed against penalty by tax tribunal decision. Income tax tribunal put a
penalty of 75million Rupees as they believe company expressed excessive payments to imports in
1994 annual report.
 Company is still representing that amount in balance sheet. Company has to include it in NOTES
only. This will make Current Ratio and Quick Ratio even lower but it will represent a true image of
company.

RECOMMENDATIONS

 Company has to reduce their debt as it is affecting their performance

 Company has to reduce their cost of raw material and packaging.
 Company has to improve their reporting by adding provisions for pending lawsuits.